ROS1 and non-small cell lung carcinoma: Fusion gene detection is mandatory for the initial evaluation of advanced NSCLC, as various agents that target fusion gene kinase (eg, ALK or ROS1) have proven effective against fusion gene‐derived tumors and been approved.